ECM
LRMR icon

Element Capital Management’s Larimar Therapeutics LRMR Stock Holding History

Element Capital Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,945
Closed -$174K – 934
2018
Q1 		$174K Buy
+1,945
New +$165K ﹤0.01% 712
2017
Q3 		– Sell
-7,510
Closed -$316K – 85
2017
Q2 		$316K Buy
+7,510
New +$384K 0.06% 67

Other funds holding LRMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

Element Capital Management's LRMR Position: Q2 2018 in Review

Element Capital Management sold out of Larimar Therapeutics (LRMR) in Q2 2018, closing a stake of 1,945 shares — an estimated $174K sold.

Element Capital Management first reported a position in LRMR in Q2 2017 and held it in 2 quarters. The position peaked at $316K in Q2 2017. 87 funds tracked by Wall St. Rank hold LRMR as of Q2 2018.

  • Element Capital Management reported no remaining Larimar Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Element Capital Management sold 1,945 Larimar Therapeutics shares in Q2 2018, an estimated $174K.
  • Element Capital Management first reported a position in Larimar Therapeutics in Q2 2017 and held it in 2 quarters.
  • Element Capital Management's Larimar Therapeutics position peaked at $316K in Q2 2017.
  • 87 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2018.

Based on Element Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.